A CK2-dependent mechanism for degradation of the PML tumor suppressor

被引:251
作者
Scaglioni, Pier Paolo
Yung, Thomas M.
Cai, Lu Fan
Erdjument-Bromage, Hediye
Kaufman, Andrew J.
Singh, Bhuvanesh
Teruya-Feldstein, Julie
Tempst, Paul
Pandolfi, Pier Paolo
机构
[1] Mem Sloan Kettering Canc Ctr, Canc Biol & Genet Program, Sloan Kettering Inst, New York, NY 10021 USA
[2] Mem Sloan Kettering Canc Ctr, Dept Med, New York, NY 10021 USA
[3] Mem Sloan Kettering Canc Ctr, Dept Pathol, New York, NY 10021 USA
[4] Mem Sloan Kettering Canc Ctr, Program Mol Biol, Sloan Kettering Inst, New York, NY 10021 USA
[5] Mem Sloan Kettering Canc Ctr, Dept Surg, New York, NY 10021 USA
关键词
D O I
10.1016/j.cell.2006.05.041
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
The PML tumor suppressor controls key pathways for growth suppression, induction of apoptosis, and cellular senescence. PML loss occurs frequently in human tumors through unknown posttranslational mechanisms. Casein kinase 2 (CK2) is oncogenic and frequently upregulated in human tumors. Here we show that CK2 regulates PML protein levels by promoting its ubiquitin-mediated degradation dependent on direct phosphorylation at Ser517. Consequently, PML mutants that are resistant to CK2 phosphorylation display increased tumor-suppressive functions. In a faithful mouse model of lung cancer, we demonstrate that Pml inactivation leads to increased tumorigenesis. Furthermore, CK2 pharmacological inhibition enhances the PML tumor-suppressive property in vivo. Importantly, we found an inverse correlation between CK2 kinase activity and PML protein levels in human lung cancer-derived cell lines and primary specimens. These data identify a key posttranslational mechanism that controls PML protein levels and provide therapeutic means toward PML restoration through CK2 inhibition.
引用
收藏
页码:269 / 283
页数:15
相关论文
共 44 条
[11]   Development of a flexible and specific gene delivery system for production of murine tumor models [J].
Fisher, GH ;
Orsulic, S ;
Holland, E ;
Hively, WP ;
Li, Y ;
Lewis, BC ;
Williams, BO ;
Varmus, HE .
ONCOGENE, 1999, 18 (38) :5253-5260
[12]   The function of PML in p53-dependent apoptosis [J].
Guo, A ;
Salomoni, P ;
Luo, JY ;
Shih, A ;
Zhong, S ;
Gu, W ;
Pandolfi, PP .
NATURE CELL BIOLOGY, 2000, 2 (10) :730-736
[13]   Loss of the tumor suppressor PML in human cancers of multiple histologic origins [J].
Gurrieri, C ;
Capodieci, P ;
Bernardi, R ;
Scaglioni, PP ;
Nafa, K ;
Rush, LJ ;
Verbel, DA ;
Cordon-Cardo, C ;
Pandoli, PP .
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2004, 96 (04) :269-279
[14]   Phosphorylation of PML by mitogen-activated protein kinases plays a key role in arsenic trioxide-mediated apoptosis [J].
Hayakawa, F ;
Privalsky, ML .
CANCER CELL, 2004, 5 (04) :389-401
[15]   CK2 is a C-terminal IκB kinase responsible for NF-κB activation during the UV response [J].
Kato, T ;
Delhase, M ;
Hoffmann, A ;
Karin, M .
MOLECULAR CELL, 2003, 12 (04) :829-839
[16]   A DNA damage-induced p53 serine 392 kinase complex contains CK2, hSpt16, and SSRP1 [J].
Keller, DM ;
Zeng, XY ;
Wang, Y ;
Zhang, QH ;
Kapoor, M ;
Shu, HJ ;
Goodman, R ;
Lozano, G ;
Zhao, YM ;
Lu, H .
MOLECULAR CELL, 2001, 7 (02) :283-292
[17]  
KOKEN MHM, 1995, ONCOGENE, V10, P1315
[18]   Role of promyelocytic leukemia (PML) sumolation in nuclear body formation, 11S proteasome recruitment, and As2O3-induced PML or PML/retinoic acid receptor α degradation [J].
Lallemand-Breitenbach, V ;
Zhu, J ;
Puvion, F ;
Koken, M ;
Honoré, N ;
Doubeikovsky, A ;
Duprez, E ;
Pandolfi, PP ;
Puvion, E ;
Freemont, P ;
de Thé, H .
JOURNAL OF EXPERIMENTAL MEDICINE, 2001, 193 (12) :1361-1371
[19]   Protein kinase CK2 in mammary gland tumorigenesis [J].
Landesman-Bollag, E ;
Romieu-Mourez, R ;
Song, DH ;
Sonenshein, GE ;
Cardiff, RD ;
Seldin, DC .
ONCOGENE, 2001, 20 (25) :3247-3257
[20]  
LAVAU C, 1995, ONCOGENE, V11, P871